Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease

被引:76
作者
Fitzmaurice, PS
Ang, L
Guttman, M
Rajput, AH
Furukawa, Y
Kish, SJ
机构
[1] Ctr Addict & Mental Hlth, Human Neurochem Pathol Sect, Human Neurochem Pathol Lab, Toronto, ON M5T 1R8, Canada
[2] Univ Western Ontario, Hlth Sci Ctr, Div Neuropathol, London, ON N6A 5C1, Canada
[3] Univ Saskatchewan, Div Neurol, Saskatoon, SK, Canada
[4] Ctr Addict & Mental Hlth, Movement Disorders Res Lab, Toronto, ON M5T 1R8, Canada
关键词
Parkinson's disease; progressive supranuclear palsy; multiple system atrophy; substantia nigra; glutathione; oxidative stress;
D O I
10.1002/mds.10486
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD. as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [-30%], PSP [-21%]), whereas a similar decrease in the MSA patient Group did not reach statistical significance (P = 0.078, MSA [-20%]). GSH levels were normal in all examined normal and degenerating extra-nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient Groups (-19 to -30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. (C) 2003 Movement Disorder Society.
引用
收藏
页码:969 / 976
页数:8
相关论文
共 40 条
[1]   Frontal lobe dysfunction in progressive supranuclear palsy: Evidence for oxidative stress and mitochondrial impairment [J].
Albers, DS ;
Augood, SJ ;
Park, LCH ;
Browne, SE ;
Martin, DM ;
Adamson, J ;
Hutton, M ;
Standaert, DG ;
Vonsattel, JPG ;
Gibson, GE ;
Beal, MF .
JOURNAL OF NEUROCHEMISTRY, 2000, 74 (02) :878-881
[2]   Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy [J].
Albers, DS ;
Augood, SJ ;
Martin, DM ;
Standaert, DG ;
Vonsattel, JPG ;
Beal, MF .
JOURNAL OF NEUROCHEMISTRY, 1999, 73 (02) :881-884
[3]   Further evidence for mitochondrial dysfunction in progressive supranuclear palsy [J].
Albers, DS ;
Swerdlow, RH ;
Manfredi, G ;
Gajewski, C ;
Yang, LC ;
Parker, WD ;
Beal, MF .
EXPERIMENTAL NEUROLOGY, 2001, 168 (01) :196-198
[4]   URIC-ACID PROVIDES AN ANTIOXIDANT DEFENSE IN HUMANS AGAINST OXIDANT-CAUSED AND RADICAL-CAUSED AGING AND CANCER - A HYPOTHESIS [J].
AMES, BN ;
CATHCART, R ;
SCHWIERS, E ;
HOCHSTEIN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :6858-6862
[5]  
[Anonymous], FREE RADIC RES
[6]   Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death [J].
Bains, JS ;
Shaw, CA .
BRAIN RESEARCH REVIEWS, 1997, 25 (03) :335-358
[7]   Expression and activity of antioxidants in the brain in progressive supranuclear palsy [J].
Cantuti-Castelvetri, I ;
Keller-McGandy, CE ;
Albers, DS ;
Beal, MF ;
Vonsattel, JP ;
Standaert, DG ;
Augood, SJ .
BRAIN RESEARCH, 2002, 930 (1-2) :170-181
[8]   URIC-ACID IS REDUCED IN THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE - EFFECT ON DOPAMINE OXIDATION [J].
CHURCH, WH ;
WARD, VL .
BRAIN RESEARCH BULLETIN, 1994, 33 (04) :419-425
[9]   URIC-ACID IRON-ION COMPLEXES - A NEW ASPECT OF THE ANTIOXIDANT FUNCTIONS OF URIC-ACID [J].
DAVIES, KJA ;
SEVANIAN, A ;
MUAKKASSAHKELLY, SF ;
HOCHSTEIN, P .
BIOCHEMICAL JOURNAL, 1986, 235 (03) :747-754
[10]  
DEXTER DT, 1992, ANN NEUROL, V32, P94